Please click
 User   Pwd      Remember
Article Search: 
BiotechEast
· Home
· About us
· Services
· FAQ
· Contact us
Info Resources
· Companies
· Institutes
· Science parks
· Life science news
· Company spotlight
· Taiwan bio report
· Feature articles
· Asia-Pacific events
· Investment corner
· Technology transfer
· Int'l biotech links
· Info resources search
· Job listings
· Log out
Partners
Previous  8 9 10 11 12 13 14 15 16 17 ... Total pages:255  Next 

Life Science News

(Taiwan) Local company invests in botanical drug firm


(Taipei Times)

24 October, 2013
Local drug producer Genovate Biotechnology Co (健亞) yesterday said it plans to invest US$1 million to buy a 1.42 percent stake in China-based PuraPharm Corp (培力) to co-develop botanic drugs aimed at curing central nervous system and metabolic disorders.
More...




Life Science News

(China) China Pushes Genetically Modified Food


(Wall Street Journal)

23 October, 2013
Caught between rising pressures to increase its food resources and popular skepticism over allowing more genetically modified food, China’s government is stepping up a public-relations campaign that could pave the way toward full approval for commercial production of these politically sensitive crops.
More...




Life Science News

(Taiwan) Astrazeneca Allies with Taiwan in Drug Repurposing Project


(BioWorld)

18 October, 2013
Astrazeneca plc and Taiwan’s National Research Program for Biopharmaceuticals (NRPB) are collaborating to repurpose a basket of clinical-stage drug candidates provided by the London-based big pharma for possible new therapies targeting Asian-prevalent diseases, using an open innovation model of development.
More...




Life Science News

(China) Dance Biopharm announces JV with Harmony Asset for the development of its inhaled insulin product


(BiotechEast staff)

15 October, 2013
Dance Biopharm Inc., a San Francisco-based biotechnology company focused on the development of inhaled insulin products to treat diabetes, this week announced that it had entered into a joint venture with Hong Kong-based Harmony Asset for the development of Adagio, a novel inhaled insulin product, in China and other Asian countries (excluding Japan).




Life Science News

(Taiwan) Taiwan clinics cash in on Chinese health check visitors


(Wantchinatimes.com)

15 October, 2013
Taiwanese clinics are cashing in on the increasing number of Chinese tourists visiting the island for health checks after restrictions were eased last year, Want Daily reports.
More...




Life Science News

(Taiwan) Taiwan looks to first vaccine against fatal H7N9 avian flu


(Medical Xpress)

14 October, 2013
Taiwan is scheduled to roll out its first vaccine against the H7N9 strain of avian flu in late 2014, after the island confirmed the first outbreak of the deadly virus earlier this year, researchers said Monday.
More...




Life Science News

(China) China-made encephalitis vaccine gets WHO safety seal


(www.scidev.net)

13 October, 2013
A Chinese-produced vaccine to protect children against deadly Japanese encephalitis has been prequalified in safety and efficacy terms by the WHO. It is the first Chinese-made vaccine to gain WHO’s stamp of approval.
More...






Life Science News

(China) Amway to build botanical research center in Wuxi


(Wantchinatimes.com)

12 October, 2013
Amway, the American direct-selling company that markets health, beauty and home care products, announced that it will begin construction of the world's first Nutrilite botanical research center in Wuxi in eastern China's Jiangsu province to make products targeting the multi-billion Chinese market. The company will invest up to US$25 million in this center to study the possibilities of combining western biotechnology with traditional Chinese medicinal herbs, and roll out new products targeting Chinese consumers.
More...




Life Science News

(Taiwan) GNTbm licenses novel cancer drug candidate from Shenzhen Chipscreen Biosciences


(BiotechEast staff)

10 October, 2013
Taiwan's GNT Biotech and Medicals Corporation (GNTbm) announced this week the granting of an exclusive license from Shenzhen Chipscreen Biosciences Ltd. for the development and commercialization of Chidamide in Taiwan. Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by Chipscreen Biosciences in Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) and Non-Small Cell Lung Cancer patients (NSCLC). GNTbm has stated that it intends to develop and commercialize Chidamide primarily in PTCL, NSCLC and will also retain the rights to develop and commercialize Chidamide in other oncology indications in Taiwan.




Life Science News

(Taiwan) Taiwan inaugurates MMS promotion office


(Taiwan Today)

4 October, 2013
A medical management service promotion office was inaugurated by the ROC Ministry of Health and Welfare Oct. 3 in Taipei City, a key development in Taiwan’s drive to become a global MMS leader.
More...




Sponsors

Events











Taiwan Life Sciences Bulletin

Enter email address to receive free e-newsletter


Sample

Disclaimer and Privacy Policy